CCCC vs. KPTI
CCCC (C4 Therapeutics, Inc.) and KPTI (Karyopharm Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CCCC returned -38.85%/yr vs -43.70%/yr for KPTI. At a 0.31 correlation, their price movements are largely independent.
Performance
CCCC vs. KPTI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CCCC achieves a 87.96% return, which is significantly higher than KPTI's 15.49% return.
CCCC
- 1D
- -6.75%
- 1M
- 21.69%
- YTD
- 87.96%
- 6M
- 41.34%
- 1Y
- 107.51%
- 3Y*
- 1.04%
- 5Y*
- -38.85%
- 10Y*
- —
KPTI
- 1D
- -6.39%
- 1M
- -1.62%
- YTD
- 15.49%
- 6M
- 44.31%
- 1Y
- 89.31%
- 3Y*
- -36.47%
- 5Y*
- -43.70%
- 10Y*
- -23.75%
CCCC vs. KPTI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
CCCC C4 Therapeutics, Inc. | 87.96% | -46.94% | -36.28% | -4.24% | -81.68% | -2.81% | 29.97% |
KPTI Karyopharm Therapeutics Inc. | 15.49% | -27.45% | -21.82% | -74.56% | -47.12% | -58.46% | 8.78% |
Correlation
The correlation between CCCC and KPTI is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.26 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Oct 5, 2020 | 0.31 |
Fundamentals
CCCC:
$452.61M
KPTI:
$210.08M
CCCC:
-$1.18
KPTI:
-$13.00
CCCC:
11.02
KPTI:
0.84
CCCC:
$28.71M
KPTI:
$151.12M
CCCC:
$26.90M
KPTI:
$145.13M
CCCC:
-$107.31M
KPTI:
-$93.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CCCC vs. KPTI — Risk / Return Rank
CCCC
KPTI
CCCC vs. KPTI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for C4 Therapeutics, Inc. (CCCC) and Karyopharm Therapeutics Inc. (KPTI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CCCC | KPTI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.11 | ||
| Sortino ratioReturn per unit of downside risk | +0.25 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.22 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 2.08 | 1.86 | +0.22 |
| Martin ratioReturn relative to average drawdown | 4.02 | 4.59 | -0.57 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CCCC | KPTI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.07 | 0.95 | +0.11 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.33 | -0.46 | +0.13 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.28 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.26 | -0.27 | +0.01 |
Drawdowns
CCCC vs. KPTI - Drawdown Comparison
The maximum CCCC drawdown since its inception was -97.82%, roughly equal to the maximum KPTI drawdown of -99.50%. Use the drawdown chart below to compare losses from any high point for CCCC and KPTI.
Loading charts...
Drawdown Indicators
| CCCC | KPTI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.82% | -99.50% | +1.68% |
Max Drawdown (1Y)Largest decline over 1 year | -52.10% | -48.36% | -3.74% |
Max Drawdown (3Y)Largest decline over 3 years | -90.00% | -89.32% | -0.68% |
Max Drawdown (5Y)Largest decline over 5 years | -97.82% | -98.36% | +0.54% |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.15% | — |
Current DrawdownCurrent decline from peak | -92.89% | -98.80% | +5.91% |
Average DrawdownAverage peak-to-trough decline | -71.93% | -75.28% | +3.35% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.91% | 19.53% | +7.38% |
Volatility
CCCC vs. KPTI - Volatility Comparison
C4 Therapeutics, Inc. (CCCC) has a higher volatility of 33.23% compared to Karyopharm Therapeutics Inc. (KPTI) at 24.86%. This indicates that CCCC's price experiences larger fluctuations and is considered to be riskier than KPTI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CCCC | KPTI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 33.23% | 24.86% | +8.37% |
Volatility (6M)Calculated over the trailing 6-month period | 64.03% | 62.32% | +1.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 101.70% | 94.32% | +7.38% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 117.54% | 94.91% | +22.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 113.15% | 86.51% | +26.64% |
Dividends
CCCC vs. KPTI - Dividend Comparison
Neither CCCC nor KPTI has paid dividends to shareholders.
Financials
CCCC vs. KPTI - Financials Comparison
This section allows you to compare key financial metrics between C4 Therapeutics, Inc. and Karyopharm Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CCCC and KPTI have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CCCC has higher volatility (33.23%) compared to KPTI (24.86%). In terms of maximum drawdown, CCCC dropped -97.82% vs KPTI's -99.50%.
CCCC currently has the higher Sharpe Ratio (1.07 vs 0.95), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CCCC and KPTI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer